YK-11
Muscle & Strength · Myostatin inhibitor / SARM-like
Tier D
High-risk evidence profile
Bottom line
Read Off Label grades YK-11 as D (2.9/10) based on very weak evidence, unclear benefit magnitude, and a unknown-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
Despite frequent 'best SARM' marketing in forums, human data is functionally zero — all evidence from in vitro myoblast studies by Kanno.
Studied, labeled, or reported-use context: Typical illicit: 5-10 mg/day PO — NOT FDA-approved; gray market; banned sport; not individualized guidance.
What the evidence says
Despite frequent 'best SARM' marketing in forums, human data is functionally zero — all evidence from in vitro myoblast studies by Kanno. Steroidal backbone means it's more an oral AAS than a SARM. No human safety or efficacy data are available.
Mechanism
Structurally a steroidal SARM derivative (methylated DHT backbone); proposed dual action — partial AR agonism plus inhibition of myostatin via follistatin upregulation; in vitro data only
Studied, labeled, or reported dose & route
Typical illicit: 5-10 mg/day PO
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about YK-11's effects?
- Read Off Label rates the evidence for YK-11 as Very Weak and the benefit magnitude as unclear, producing an overall grade of D (2.9/10). Despite frequent 'best SARM' marketing in forums, human data is functionally zero — all evidence from in vitro myoblast studies by Kanno.
- What safety findings are reported for YK-11?
- YK-11 has a unknown-high risk profile in the database. Unknown-High (steroidal chemistry = likely hepatotoxic; HPG suppression; essentially no human safety data) Legal status: NOT FDA-approved; gray market; banned sport.
- What does the low Safety score for YK-11 represent?
- The Safety score is 3/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for YK-11?
- Typical illicit: 5-10 mg/day PO This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does YK-11 work?
- Structurally a steroidal SARM derivative (methylated DHT backbone); proposed dual action — partial AR agonism plus inhibition of myostatin via follistatin upregulation; in vitro data only
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.